WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets
“This data update showcases zongertinib’s strong efficacy and safety profile in patients with HER2-mutant non-small cell lung cancer with and without brain metastases,” said the presenting investigator, Dr. Gerrina Ruiter, MD., PhD., at the Department of Clinical Pharmacology and Thoracic Oncology, Netherlands Cancer Institute, Netherlands. “Patients with brain metastases historically have had a very poor prognosis and few effective treatment options. These data showed zongertinib is active in the brain and underscore its potential for patients who have not received prior radiotherapy.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo